Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The company has operations in Europe, Singapore, and the United States of America. The company develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.
Follow-Up Questions
Clinuvel Pharmaceuticals Ltd의 CEO는 누구입니까?
Dr. Philippe Wolgen은 2005부터 회사에 합류한 Clinuvel Pharmaceuticals Ltd의 Chief Executive Officer입니다.
CLVLF 주식의 가격 성능은 어떻습니까?
CLVLF의 현재 가격은 $7.43이며, 전 거래일에 decreased 0% 하였습니다.
Clinuvel Pharmaceuticals Ltd의 주요 사업 주제나 업종은 무엇입니까?
Clinuvel Pharmaceuticals Ltd은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Clinuvel Pharmaceuticals Ltd의 시가총액은 얼마입니까?
Clinuvel Pharmaceuticals Ltd의 현재 시가총액은 $372.9M입니다
Clinuvel Pharmaceuticals Ltd는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 9명의 분석가가 Clinuvel Pharmaceuticals Ltd에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 5명의 매수, 2명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다
